TUSC3 and neoplasm: Survival analysis revealed that TUSC3 downregulation was associated with poor OS (p = 0.001) and PFS (p = 0.012) in 136 patients with stage I (Figure 4C,D), but not with OS (p = 0.132) and PFS (p = 0.118) in 84 patients with stage II tumours (Figure 4E,F).